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Abstract
Background Management of pancreaticobiliary (PB) malignancies remains a clinical challenge. In this review, we focus on 
the management of oncological emergencies in PB malignancies and the potential complication of associated therapeutic 
interventions.
Methods Biobliographic review of current evidence on the management of oncological emergencies, their potential com-
plications, as well as synthesis of recommendations was performed. The pathogenesis, frequency, related symptoms as well 
as appropriate investigations are presented.
Results The oncologic emergencies in PB patients were summarised in six categories: (1) hematological (including febrile 
neutropaenia, thrombocytopenia, coagulopathies), (2) gastrointestinal (gastric outlet and biliary obstruction, gastrointestinal 
bleeding), (3) thromboembolic events, (4) ascites, (5) metabolic disorders and (6) neurologic complications. The pathogen-
esis, frequency, related symptoms as well as appropriate investigations are also presented.
Conclusion Patients with PB malignancies are at increased risk of a wide variation of medical emergencies. Clinical knowl-
edge, early recognition and collaboration with the relevant specialties are critical to manage these complications effectively, 
tailoring overall management around the actual prognosis and individuals’ expectations.
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Introduction 
The management of pancreaticobiliary (PB) malignancies 
(pancreatic cancer, gallbladder cancer, cholangiocarcinoma 
and ampullary tumours) remains a significant challenge for 
clinicians [1]. Late disease presentation, limited response 
to systemic treatments and patient comorbidities all con-
tribute to the continued dismal survival figures. In addition, 
patients with PB malignancies may present acutely with spe-
cific oncological complications related to features of local 
disease infiltration, tumour stimulated paraneoplastic condi-
tions or treatment related side effects. Clinicians need to be 
aware of these to allow provision of appropriate support in 
a timely manner with optimal utilisation of health resources. 
This review focuses on key oncological emergencies and 
acute complications observed in PB malignancies, focus-
ing on their management and the potential complications of 
associated therapeutic interventions (Fig. 1).
Hematological
Febrile Neutropaenia
Febrile neutropaenia (FN), almost always secondary to the 
effects of chemotherapy, is defined as an oral temperature 
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of > 38.3  °C or two consecutive readings of > 38.0  °C 
for 2  h and an absolute neutrophil count (ANC) 
of < 0.5 ×  109/L, or expected to fall below 0.5 ×  109/L [2]. 
Although FN can cause significant morbidity and mor-
tality, early diagnosis and aggressive supportive manage-
ment, particularly commencement of intravenous antibiot-
ics, has significantly improved outcomes with less than 5% 
of cases in England requiring intensive care management. 
Use of the internationally recognised Multinational Asso-
ciation of Supportive Care in Cancer (MASCC) prognostic 
index can help to stratify the clinical management of FN, 
depending on risk of mortality [3].
Frequency
The incidence of chemotherapy-induced FN in PB can-
cer varies between reported studies but is generally low 
(Table 1). The use of combination chemotherapy with 
irinotecan, oxaliplatin and 5FU in metastatic pancreatic 
ductal cancer produces a high rate of grade 3/4 neutropae-
nia but sepsis is rare [4]. Although primary G-CSF proph-
ylaxis was not allowed within the trial, 42% of patients on 
FOLFIRINOX required it as secondary prophylaxis after 
severe neutropaenia. Modifications of the FOLFIRINOX 
regimen with, for example, lowering of the irinotecan dose 
and removal of bolus 5FU, are often made thus reducing 
the risk of FN.
Of interest, the incidence of FN observed with gemcit-
abine (7%) and gemcitabine/cisplatin (10%) regimens used 
in the ABC-02 study for advanced biliary tract cancers, was 
higher than observed in pancreatic cancer studies [5]. One 
explanation for this may be the approximately threefold 
higher presence of biliary stents, as seen within ABC-02 
participants, as opposed to pancreatic studies with the asso-
ciated increased risk of biliary sepsis.
Management
In case of suspected NF, immediate empiric antibiotic treat-
ment should be considered, with a broad spectrum antibiotic 
(usually beta lactam monotherapy with piperacillin/tazobac-
tam, except when patient-specific or local microbiological 
contraindications dictate), ideally to commence within one 
hour of presentation. Thereafter, management can follow 
risk stratification. High-risk patients (MASCC < 21) should 
be admitted to continue on intravenous antibiotics and 
other supportive measures. Low-risk group (MASCC ≥ 21, 
haemodynamically stable, without evidence of organ failure, 
pneumonia, an indwelling venous catheter or severe soft tis-
sue infection) can be treated with antibiotics such as combi-
nation quinolone with amoxicillin plus clavulanic acid [6] 
or oral moxifloxacin, as an outpatient [7].
The use of granulocyte colony-stimulating factors 
(G-CSFs) in treatment of chemotherapy-induced FN has 
not been shown to improve overall survival but can induce a 
faster recovery from fever and shorter hospital stay [8]. Use 
of G-CSF to prevent recurrence of FN (secondary prophy-
laxis) is common with FOLFIRINOX with occasional use 
as primary prophylaxis.
Thrombocytopenia
Thrombocytopenia is, in itself, not recognised as an onco-
logic emergency but chemotherapy regimens associated with 
Fig. 1  Pancreaticobiliary 
complications. STE systemic 
thromboembolic events, DIC 
disseminated intravascular 
coagulation, GOO gastric outlet 
obstruction, SVT splanch-
nic vein thrombosis, SIADH 
syndrome of inappropriate 
antidiuretic hormone secretion, 
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treatment of PB malignancies do have a high incidence of 
grade 3 (< 50.0–25.0 ×  109/L) and 4 (< 25.0 ×  109 /L) tox-
icity. This can be up to 40% (12% grade 4) with certain 
combinations of gemcitabine and cisplatin [9] but in the 
registration studies of the most commonly used regimens 
was around 10%, with rates of the more clinically concern-
ing grade 4 toxicity not individually reported [4, 5, 10]. The 
management of thrombocytopenia is driven by any bleed-
ing symptoms aiming to maintain the platelet level above 




Frequency PB cancers are known to be associated with 
an increased risk of thrombotic events. A 6-year study of 
pulmonary embolism (PE) incidence in cancer outpa-
tients showed PB cancers accounting for almost 13% of all 
detected PE with a relative risk of 2–2.5 × that of the average 
cancer patient [12]. Thrombosis can be the first manifesta-
tion of an otherwise undiagnosed cancer and PB cancers 
may account for 15% of cancer associated PE/DVT present-
ing in this manner [13].
Up to 60% of venous thromboembolic events (VTEs) 
in PB cancer patients may present asymptomatically [14]. 
Alternatively, common presenting manifestations of acute 
peripheral deep vein thrombosis (DVT); limb oedema, pain, 
erythema, or of PE; breathlessness, chest pain and tachyp-
noea may be masked in cancer patients by other features of 
their disease.
Arterial thrombosis may also be increased in PB can-
cer. An analysis from 4 stroke units in France over a 7-year 
period recorded 17 cases of ischaemic stroke in patients with 
pancreatic cancer [15]. In 7 of these patients, the onset of the 
stroke led to the cancer diagnosis. Non-bacterial thrombotic 
endocarditis was detected in about a third of the patients by 
cardiac ultrasound. Outcome was very poor for all patients 
irrespective of anticoagulation.
Investigations Predictive clinical models, such as the Wells 
or revised Geneva score, may help in assessing the risk of 
VTE in cancer patients [16]. D-dimer levels in PB cancer 
patients may be elevated as part of the hypercoagulable 
state, even in the absence of VTE, resulting in a threefold 
higher rate of false positives. However, if not elevated they 
can help in exclusion of VTE in cancer patients and save 
further investigations.
Duplex ultrasonography of limb veins remains the prin-
ciple diagnostic test for DVT. CT or MRI can be used for 
looking at deep pelvic veins. CT pulmonary angiography 
is routinely used to detect PE with a high sensitivity, and 
negative predictive value > 94% [17].
Table 1  Representative phase III studies indicating the frequency of grade 3/4 neutropaenia and FN in PB cancers
Neut: grade 3: < 1000–500/mm3; grade 4: < 500/mm3; PLTs: grade 3 < 50,000–25,000/mm3; grade 4: < 25,000/mm3
CAP capecitabine, CDDP cisplatin, FN febrile neutropaenia, GEM gemciatbine, NR not reported
Author (trial) Line of Tx Treatment arms Neutropenia 
(%)
Gr 3/4
FN (%) Thrombocytopenia 
(%)
Gr 3/4
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Aetiology Notable advances have been made over recent 
years in our understanding of the molecular mechanisms 
underlying cancer related thrombosis. Tissue Factor, a 
transmembrane protein found normally in sub-endothelial 
tissue [18], cancer associated mucins and the protein podo-
planin expressed in PB cells [19] can stimulate the extrin-
sic coagulation pathway and activate platelets to stick to 
endothelial cells and leukocytes resulting in formation of 
micro-thrombi. Tumour-associated activated neutrophils 
release histone-bound DNA fragments with associated 
granular proteins. Although these neutrophil extracellular 
traps (NET) have ostensibly an immune protective function 
they contribute to the pro-coagulant environment by captur-
ing activated platelets and micro-vesicles [20].
Patient-related factors also contribute to the risk of 
thrombosis development. The administration of certain 
cytotoxic drugs, e.g., platinums, is known to have a pro-
coagulant effect, as seen by the increase in VTE events in 
patients on chemotherapy compared to those not on treat-
ment [21]. However, exact mechanisms underlying this 
remain unclear. Similarly, indwelling venous catheters to 
deliver chemotherapy are associated with an increased risk 
of venous thrombosis [22].
Management Low molecular weight heparins are a more 
effective first-line treatment compared to vitamin K antago-
nists such as warfarin [23]. The optimal duration of antico-
agulation remains unproven; however, recent evidence sug-
gests that continuing anticoagulation, of whatever form, for 
over 6 months had a significant benefit in terms of reduced 
incidence of further VTE than only being on treatment for 
0–3  months [24]. Many patients find long-term self- 
administration of LMWH problematic, and the direct oral anti-
coagulants (DOACs) have become an alternative first-line 
treatment for cancer-related VTE. Large, randomised, non- 
inferiority trials of edoxaban, rivaroxaban and apixaban 
compared to LMWH in cancer-induced VTE have shown 
equivalence in terms of reducing VTE recurrence [25–27] 
(Table 2), with small but significant increases in the risk 
of clinically relevant bleeding and more frequent drug- 
drug interactions needing to be taken into consideration. As 
experience becomes greater with the new agents, it may be 
that the type of anticoagulant used during hospitalisation 
and out-of-hospital periods for cancer patients with VTE 
will vary.
A number of trials looking at the role of prophylactic 
LMWH and DOACs in pancreatic cancer, or where pancre-
atic cancer formed a large proportion of the trial cohort, have 
been published [28, 29] (Table 3). They show significant 
reductions in the risk of VTE, both incidental and sympto-
matic, but as yet it is unclear as to whether they impact on 
overall survival. Our greater understanding of the molecu-
lar basis underlying PB cancer hypercoagulability may ulti-
mately allow patient tailored prophylactic anticoagulation 
therapy in future.
Disseminated intravascular coagulation (DIC)
The most extreme manifestation of activation of the coagula-
tion system is disseminated intravascular coagulation (DIC). 
Overt DIC is uncommon in PB malignancy but has a very 
poor prognosis.
Symptoms
The commonest form of DIC in PB malignancy is ‘procoag-
ulant’, where excess thrombin generation causes both micro-
vascular and macrovascular thrombosis. However, the hyper-
fibrinolytic form, where an increased risk of bleeding due 
to activation of the fibrinolytic system is dominant, has also 
Table 2  Treatment of cancer-related venous thromboembolic event (VTE)
CRNMB clinically relevant non-major bleeding
Trial Direct oral anticoagulant Patient number Recurrent VTE Major bleed CRNMB Fatal bleed
Carravagio 
[27]
Apixaban 10 mg bd for 7 days, then 5 mg bd 576 5.60% 3.8% (1.9% GI) 9.00% 0
Dalteparin 200 IU sc. daily for 1 month then 150 IU 
sc. daily




Edoxaban 60 mg/day 522 7.90% 6.90% 14.60%
Dalteparin 200 IU sc. daily for 1 month then 150 IU 
sc. daily
524 11.30% 4.00% 11.10%
Treatment for at least 6 months–extension to 
12 months at medical discretion
SELECT-D 
[26]
Rivaroxaban 203 4% 5.50% 12%
Dalteparin 200 IU sc. daily for 1 month then 150 IU 
sc. daily
203 9% 3% 3.50%
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been reported in pancreatic cancer [30]. At its most extreme 
patients can present with multiple thromboses in peripheral 
or visceral vessels, bleeding with associated thrombocyto-
penia or a combination of both.
Investigations
Interpretation of coagulation blood tests can be challenging 
in cancer-associated DIC. The prothrombin time (PT) and 
partial thromboplastin time (PTT) may not be prolonged 
in subclinical DIC, and paradoxically the PTT can even be 
decreased initially [30, 31]. Fibrinogen levels are not usu-
ally altered in pro-coagulant DIC but may be significantly 
reduced in hyperfibrinolytic disease.
Management
There is no clear consensus regarding the optimal manage-
ment strategy; however, patients should be assessed to iden-
tify those with high risk of bleeding and those with high 
risk of thrombosis [30, 31]. Precipitating factors, such as 
sepsis, should be considered and treated if present. Appro-
priate treatment of the cancer is considered to be the first-
line strategy for cancer-related DIC. Anticoagulation with 
therapeutic-dose of low molecular weight heparin (LMWH) 
for 6 months, especially when thrombosis is clinically overt, 
in the presence of satisfactory platelets counts, is safe and 
superior to warfarin in preventing recurrence of thromboem-
bolic events [31, 32]. Platelets and plasma support showed 
proven efficacy in patients with low platelets and bleeding 
risk. Other measures include concentrate of anti-thrombin III 
inhibitor and supplementation of activated protein C.
Complications of Management
Bleeding is a known complication of DIC treatment espe-
cially if anticoagulation monitoring is suboptimal. Increased 
risk of clotting is also noted in patient receiving clotting 
factors to correct coagulopathy. Other less common com-
plication associated with transfusion reactions.
Gastrointestinal
Gastric Outlet Obstruction and Functional 
Gastroparesis
Frequency
In pancreaticobiliary cancers, gastric outlet obstruction 
(GOO) occurs in around 5% of patients at presentation 
with a further 10–20% of patients developing GOO dur-
ing the course of the disease [33–36]. Gastroparesis, a 
disorder characterised by delayed emptying of gastric 
contents with resulting nausea, vomiting and upper 
abdominal fullness, is potentially even more common in 
PB malignancy. Reported as occurring in 60% of patients 
with pancreatic cancer [37], half of whom showed symp-
toms, causes may relate to tumour infiltration into auto-
nomic neural plexuses, medication or, rarely, paraneo-
plastic phenomena.
Symptoms
GOO may present acutely with nausea and vomiting which 
may be projectile and large volume with undigested food 
residue. Patients often have a feeling of epigastric full-
ness or discomfort which is relieved by vomiting. If left 
untreated, it may lead to dehydration and cachexia with 
repeated episodes of vomiting risking aspiration pneumo-
nia. However, GOO-like gastroparesis can also develop 
insidiously with early satiety, decreased appetite and 
weight loss, worsening reflux symptoms and severely 
reduces the patients’ quality of life (QoL) [36].
Investigations
Unlike small intestinal obstruction, features of GOO may not 
be obvious on abdominal X-ray despite similarities in acute 
symptoms. CT imaging is the mainstay of diagnosis allow-
ing identification of tumour location and its relationship to 
adjacent structures. It is important to look for secondary 
Table 3  Prophylaxis for cancer-associated venous thromboembolic event
CRNMB clinically relevant non-major bleeding
Direct oral anticoagulant Patient number Khorana score 2/ > 2 VTE (DVT/PE) Major bleed CRNMB
Cassini 
[29]
Rivaroxaban 10 mg daily for 180 days 420 286 24 (15/5) 8 11
Placebo 421 298 37 (19/5) 4 8
Avert 
[28]
Apixaban 2.5 mg bd for 180 days 291 63.9/26.1 12 (7/5) 10 21
Placebo 283 67.1/23.9 28 (12/16) 5 15
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sites of obstruction beside the primary PB tumour itself. 
This can include locoregional lymph nodes and peritoneal 
disease involving distal segments of bowel. If peritoneal dis-
ease is present, good palliation is much harder to achieve. 
For more accurate information on the extent of obstruction 
and to plan effective treatment, a barium meal or gastroscopy 
may be helpful.
If no obvious site of mechanical obstruction is determined 
despite symptoms, a gastric emptying study may be required 
to identify gastroparesis. It is an important diagnosis to make 
in view of its prevalence, up to 60% of PB malignancies, and 
being misattributed as cancer cachexia or chemotherapy-
induced nausea and vomiting.
Management
The treatment goal is to reestablish oral feeding and resolve 
symptoms by restoring gastrointestinal continuity. Opera-
tive resection is the best treatment if the cancer is poten-
tially resectable. If at the time of laparotomy, the tumour is 
found to be unresectable, then operative bypass should be 
performed. This is because there is a 28% risk of developing 
GOO during follow-up [38].
For patients with upfront unresectable disease, there is 
no consensus for treatment of malignant GOO. Since the 
1990s, the traditional, open gastrojejunostomy (OGJ) has 
been replaced by either endoscopic duodenal stenting (DS) 
or laparoscopic gastrojejunostomy (LGJ) [36]. DS is associ-
ated not only with a shorter length of stay (LOS) and faster 
symptom relief but also with an increased risk of symptom 
recurrence and need for reintervention [35, 39, 40]. Most 
DS procedures can be performed as an outpatient procedure, 
and patients can introduce a soft diet from the following day. 
For patients undergoing LGJ, oral diet can be reintroduced 
between 4 and 10 days post-op [41]. A systematic review 
showed that the clinical success was 89% for DS and 72% 
for LGY [42].
The decision between DS and LGJ should be based on 
performance score, comorbidities and nutritional status (all 
of which if impaired should favour DS), while longer pre-
dicted survival favours LGJ. It is important to remember that 
the mean survival times after a diagnosis of GOO is only 7 
to 20 weeks [35, 43]. Many commentators now believe that 
DS achieves a better palliative result for most patients. This 
is because it minimises pain, time in hospital and physiologi-
cal stress, while not differing from LGJ in terms of survival 
or overall complications [39]. The exception to this would 
be patients with a high performance score undergoing com-
bination chemotherapy such as FOLFIRINOX with a longer 
predicted survival time.
A third alternative option for palliation is rapidly emerg-
ing. The use of endoscopic ultrasound (EUS) and lumen 
apposing metal stents to create an endoscopic gastrojeju-
nostomy. Early data, which needs replicating, suggests the 
technique may provide benefits over both alternatives and 
reduce complications [44] (Fig. 2). It may also be of benefit 
when altered anatomy or severe proximal duodenal obstruc-
tion precludes standard stenting options.
If nausea and vomiting occur in the absence of mechani-
cal obstruction, then malignant gastroparesis should be con-
sidered. Initial treatment should include review of poten-
tially contributing medications such as calcium channel 
blockers, opioid analgesics and tricyclic antidepressants, 
and any coexisting diabetes should be optimised. The next 
step is usually to offer dietary and behavioural modifications 
including having small, frequent, low-fat, low-residue meals. 
Prokinetics and antiemetics form the mainstay of pharmaco-
logical therapy and the treatments are the same as for non-
cancer gastroparesis. Erythomycin appears the most potent 
agent for stimulating gastric emptying when compared with 
domperidone, metoclopramide or cisapride [45].
Fig. 2  The three current 
approaches for GOO. A Lapa-
roscopic gastrojejunostomy 
(LGJ). B Endoscopic duodenal 
stenting (DS). C Endoscopic 
gastrojejunostomy ( adopted 
from Troncone E, Fugazza 
A, Cappello A, Blanco GDV, 
Monteleone G, Repici A, Teoh 
AYB, Anderloni A. Malignant 
gastric outlet obstruction: 
which is the best therapeutic 
option? World J Gastroenterol 
2020; 26(16): 1847–1860)
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Complications from Management (Procedures)
The significant early complications from DS include 
bleeding and perforation, occurring in around 1% of cases. 
Longer term, tumour ingrowth or stent migration has been 
reported in up to 23% of cases [46]. Late complications 
occurred in 17% of LGJ including anastomotic leakage and 
dysfunction of the LGJ [42].
Biliary Obstruction
Frequency
Approximately 70% of patients with pancreatic cancer 
present with Malignant Biliary Obstruction (MBO) [47]. 
Cholangiocarcinoma and gallbladder cancer also com-
monly cause obstruction through direct compression, hilar 
node spread or metastatic disease. Ampullary cancer while 
rare almost always causes MBO.
Symptoms
MBO leads to painless jaundice, pruritus, pale stools, dark 
urine, lethargy, anorexia, nausea and vomiting.
Investigations
Blood tests will confirm raised (conjugated) bilirubin 
along with other cholestatic liver enzymes. Tumour 
markers such as carbohydrate antigen 19–9 (CA 19–9) 
will also be raised, but this can occur in benign causes 
of biliary obstruction and is seldom clinically useful 
[47]. Liver ultrasound can help identify biliary obstruc-
tion and whether intra-hepatic or extra-hepatic. However, 
it is often not sufficient by itself to identify the cause 
and guide subsequent management and, in most cases, a 
CT is required to provide cross-sectional imaging of the 
obstruction.
When MBO occurs de novo radiological investiga-
tions need to accurately stage the causative disease. 
Appropriately protocolled CT can help define resect-
ability by describing local and distant disease, with 
CT angiography evaluating invasion or involvement of 
regional arteries and veins. In MBO arising at the hilar 
and intrahepatic regions, further anatomical assessment 
is often required. The most accurate modality in this 
case is magnetic resonance cholangiopancreatography 
(MRCP), with a sensitivity exceeding 96% and a speci-
ficity of 85% for distinguishing benign from malignant 
biliary obstruction. It also allows procedural planning 
for resectability and in palliative cases provides a road 
map for biliary drainage, for example by helping deter-
mine whether endoscopic or percutaneous approaches 
are feasible. [47].
Management
If the lesion is resectable and the patient fit enough, then 
the optimal biliary drainage approach is surgical resec-
tion. The issue of preoperative biliary drainage (PBD) 
has been controversial for many years been. A large recent 
meta-analysis suggested that avoiding PBD as a default 
position is associated with better outcomes. Notable 
exceptions include presence of cholangitis or intracta-
ble pruritus [47]. Decisions based on a bilirubin level 
remain contentious and while a level of 250 μmol/l has 
been advocated as requiring PBD a better more practical 
approach is to offer drainage if surgery is likely to be 
delayed (> 2 weeks), and in patients undergoing neoadju-
vant chemotherapy. This later group is becoming increas-
ingly common with the promotion of novel regimes, such 
as FOLFIRINOX.
In non-resectable disease, ERCP is the first-line 
approach to biliary drainage for all but a subsection of 
perihilar lesions. It is preferred to surgery because opera-
tive morbidity and mortality is high (up to 25% in some 
series) [48]. Compared to PTC, it is associated with lower 
rate of adverse events (8.6 vs 12.3%), as well as fewer 
repeat procedures, shorter hospitalisation, lower costs and 
the avoidance of external drainage catheters [48]. When 
obtaining biliary drainage the best approach is to use self-
expanding metal stents (SEMS), instead of plastic stents, 
as these are proven to be associated with longer patency, 
lower complication rates, fewer reinterventions and longer 
patient survival [49, 50].
In approximately 10% of cases, ERCP may not be pos-
sible, for example due to proximal duodenal obstruction or 
altered anatomy post-surgery. In this situation, the emerg-
ing role of EUS-guided extra-luminal stenting has emerged 
as a useful tool to drain the biliary tree via the stomach 
(hepaticogastrostomy (HG)) or duodenum (choledochodu-
odenostomy (CD)) [51].
In cases of perihilar obstruction, typically related to 
cholangiocarcinoma, gallbladder malignancy or nodal dis-
ease, management decisions are a little more complex. 
For patients with Bismuth I or II tumours, ERCP is still 
preferred to PTC. However, patients with more advanced 
hilar obstruction (Bismuth III or IV) are more difficult to 
palliate with ERCP (Fig. 3). A retrospective review dem-
onstrated higher success rates with PTC (93% vs 77%), 
though median survival was similar. Thus, PTC is gener-
ally favoured over ERCP in these cases [52].
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Complications from Management/Procedures
Following ERCP, the most common and potentially seri-
ous complication is pancreatitis, occurring in approxi-
mately 5% of procedures. Less common complications 
include perforation, biliary sepsis and bleeding compli-
cations from sphincterotomy [53]. Major complications 
from PTC occur in around 2 to 10% of cases, and include 
sepsis, liver abscess, bile leak, haemorrhage (subcapsular 
hematoma and pseudoaneurysm) and pneumothorax [54]. 
The presence of a biliary stent increases the chance of 
cholangitis, either biochemical or infective, with associ-
ated fever, pain and transient elevation of bilirubin and 
liver enzymes on blood tests.
Gastrointestinal Bleeding
Frequency
Around 3% of pancreatobiliary cancer patients experience 
gastrointestinal bleeding (GIB) [55]. This usually arises 
from tumour infiltration into the highly vascularised duo-
denum or, more rarely, the bile duct, stomach, jejunum or 
colon. The rare occurrence of tumour haemorrhage via 
the pancreatic duct is termed Haemosuccus Pancreati-
cus (HP). Bleeding can also occur from gastric varices 
secondary to splenic vein occlusion [56]. GIB may also 
occur from benign causes, e.g. peptic ulcer disease and 
oesophagitis.
Symptoms
Symptoms of a GIB include melaena, haematemesis, 
abdominal distention and pain. Similarly, a fall in hae-
moglobin accompanied by a rise in urea (out of pro-
portion to creatinine) is suggestive [55]. The extent 
of bleeding may range from the occult to rapid exsan-
guination, and this will dictate the speed and scope of 
investigations.
Investigations
Investigations are as for any patient with a GIB, with the 
possible exception of earlier use of cross-sectional angi-
ography, including clinical examination with digital rectal 
exam to identify melaena, blood tests (including clotting 
and platelet count) and once the patient has been appro-
priately resuscitated, early gastroscopy. In one study, 65% 
of patients with a GIB and pancreatic cancer actually had 
peptic ulcer disease (not directly linked to the tumour) 
[55]. One important caveat is that in cases of HP, bleed-
ing will be through the ampulla of Vater, and this is not 
always appreciated with standard gastroscopy. For this 
reason, full assessment requires the use of a side viewing 
gastroscope (as used in ERCP procedures) to definitely 
visualise the ampulla [57]. In cases of negative endos-
copy and ongoing GIB then triple phase CT often lead-
ing to angiography is the gold standard for diagnosis and 
therapy.
Management
Management is determined by the underlying cause. In 
the case of duodenal infiltration, transcatheter arterial 
embolisation (TAE) and endoscopic or surgical endo-
scopic hemostasis are potential treatment options. TAE 
is more appropriate for arterial embolisation, while sur-
gical hemostasis may increase complications and does 
not improve the prognosis [58]. Radiotherapy in case of 
endoscopic haemostasis failure can be an effective option 
[59, 60]. The evidence for the use of tranexamic acid in 
the control of GI bleeding is limited [61], while its role 
in PB cancers is unclear.
When the cause is HP, then the mainstay of treatment is 
coil embolisation of the accompanying pseudoaneurysm 
(usually the splenic artery). In cases of gastric variceal 
bleeding; initial control can be attempted with endoscopic 
glue injection but if ongoing then splenectomy, splenic 
artery embolisation and stenting of the splenic vein are 
the current treatment strategies [62].
Fig. 3  The Bismuth classifica-
tion for perihilar malignant 
obstruction (courtesy of 
Professor Henri Bismuth, Paris, 
France)
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Complications from Management/Procedures
Endoscopic management of peptic ulcer-associated bleeding 
is generally safe however recurrent bleeding may occur in 
up to 10% of cases [63]. Percutaneous arterial embolisation 
may be complicated by postembolisation hepatic abscesses 
or failure and rebleeding can occur in up to 25% of cases 
[64].
Thrombosis
SVT and Malignancy‑Related Portal Hypertension
Aetiology
The anatomical relationship of the splanchnic venous 
drainage (portal, splenic and mesenteric) to the pancreas, 
liver and bile duct make them particularly prone to tumour 
related obstruction or occlusion (splanchnic vein thrombo-
sis (SVT)). This can arise through extrinsic compression 
of vessels directly by tumour or lymph node metastases, by 
tumour induced thrombosis or by tumour invasion into the 
vessel. The resultant local blood flow stasis and endothe-
lial injury, along with the hypercoagulable state observed 
in PB cancers, comprises the classical Virchow’s triad of 
cancer-related thrombosis.
Epidemiology
Although there are non-malignant causes of SVT, it is 
strongly associated with malignancy. This association is 
sufficiently clear for some to suggest that development of 
SVT in patients without liver cirrhosis is a marker for occult 
malignancy with an 8% absolute cancer risk at 3 months 
[65]. In pancreatic cancer and cholangiocarcinoma, the 
increased risks of development of SVT are significant at 
between 30 to 75 times the general population risk, respec-
tively [66].
Presentation
Portal vein thrombosis (PVT) can be classified depending on 
position (main trunk, branch or both), being acute or chronic 
and whether symptomatic or asymptomatic [67].
In PVT, it is known that venous collaterals develop 
within 3–5 weeks of the acute event. Therefore, the defi-
nition of acute and chronic PVT to some extent depends 
on symptoms and the radiological presence of collaterals. 
Many cases of malignancy associated PVT arise without 
symptoms and are picked up as incidental features on imag-
ing. In addition, the features of acute PVT are similar to 
symptoms commonly seen in PB cancer, such as abdominal 
pain, fever, nausea, anorexia and early satiety. Chronic PVT 
is characterised by the development of local venous collat-
erals, the ‘portal cavernoma’, and portal hypertension with 
associated risks of gastrointestinal (GI) haemorrhage and 
hypersplenism. In a study of PVT occurring in 118 patients 
with predominantly pancreatico-biliary cancers, 38% had 
radiological features of portal hypertension and 18% had a 
GI bleed during the follow up period (median 10 months) 
[68]. Oesophageal varices were the most common source of 
bleeding; however, less common sites of varices, e.g. duo-
denum, gall bladder, are seen particularly when thrombus 
involves more distal branches of splanchnic venous system.
Hypersplenism develops in acute and chronic PVT, as 
well as in splenic vein thrombosis. Splenomegaly is usually 
detectable and reduced circulating leukocytes and platelets, 
secondary to sequestration, is observed.
Mesenteric vein thrombosis (MVT) can present vari-
ably, e.g. acutely, with onset of severe abdominal pain out 
of proportion to physical findings, or more chronically with 
abdominal pain, diarrhoea and weight loss. MVT is associ-
ated with features of mesenteric ischaemia in up to 15% of 
cases.
Thrombosis or occlusion of the splanchnic venous drain-
age can be associated with development of ascites. In this 
situation, the ascitic fluid is a transudate (low serum/ascitic 
fluid protein ratio) with few or no malignant cells. In some 
cases, it can be large volume, rapidly reaccumulating and 
causes significant morbidity.
Diagnosis
Many instances of PVT are picked up incidentally on CT in 
patients with no specific symptoms. In patients with con-
cerning symptoms Doppler ultrasound is a highly sensitive 
(~ 90%) and specific (~ 95%) initial test [66]. Differentiating 
between tumour and bland PVT relies upon specific features 
on contrast enhanced CT or MRI or use of 18F-FDG PET. CT 
and MRI are also required for diagnosis of MVT.
Treatment
There is no specific prospective clinical trial data relating 
to the use of anticoagulation in cancer related SVT. Interna-
tional guidelines on management for portal vein thrombosis, 
of any aetiology, generally recommend long-term antico-
agulation in the presence of a persisting predisposing stimu-
lus, such as cancer [69]. In general, the potential benefits of 
anti-coagulation in terms of vessel recanalisation (in acute 
SVT), thrombus progression and development or deteriora-
tion of symptoms have to be balanced with risks of toxicity. 
This is particularly with patients with portal hypertension 
and varices or other bleeding risks. Although DOACs can 
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be used in cancer-related thrombosis, careful consideration 
has to be made on a patient by patient basis with regard to 
interactions with other medications and reversibility of anti-
coagulation in event of a major GI bleed [70].
Percutaneously inserted self-expanding metal mesh 
(SEMM) endoluminal vascular stents can be used to open 
occluded portal and mesenteric veins to reduce symptoms 
arising from portal hypertension. In a study of 22 patients 
with pancreaticobiliary cancers and GI bleeding or ascites, 
placement of stents resolved symptoms in all but 2 patients 
[71]. Procedural complications were rare, but reocclusion 
occurred in 25% of patients. Patient selection may be impor-
tant as a significant difference was observed in post-stent 
overall survival depending on the palliative prognostic index 
score in another study [72].
Ascites
Frequency
Malignant ascite (MA) is a common manifestation of 
advanced pancreatic, and less frequently biliary, cancer. 
In an analysis of 180 patients with pancreatic cancer who 
developed ascites, the median time to onset of ascites from 
diagnosis was 11 months, with median survival following 
this 1.8 months [73].
Pathophysiology
The pathophysiology of ascites in PB cancers is multi-
factorial. Firstly, splanchnic vessel occlusion can result 
in extra-hepatic portal hypertension and activation of the 
renin–angiotensin–aldosterone system, resulting in water 
and sodium retention [74]. Secondly, animal studies suggest 
lymphatic obstruction as a possible underlying mechanism, 
although lymphatic blockage alone cannot explain how 
some patients, with small tumour burdens, experience large 
fluid accumulation. More recently, vascular permeability 
factors, immunomodulators and metalloproteinases have 
gained increasing interest for their role in the formation 
of MA [75]. Vascular endothelial growth factor (VEGF) 
levels are significantly increased in patients with MA com-
pared to patients with non-malignant cirrhotic ascites used 




Use of diuretics is of symptomatic benefit in less than 50% 
of patients with PB cancer associated ascites [77] although 
the underlying aetiology can help guide which patients might 
benefit more. Patients whose ascites is the result of portal 
hypertension, secondary to liver metastases or portocaval 
adenopathy, have been shown to lose up to twice as much 
fluid per day than those where peritoneal carcinomatosis is 
the underlying cause, when treated with spironolactone or 
furosemide [78]. They also had fewer problems with third 
space effects such as hypotension or renal dysfunction.
Ascitic Drainage and Cell‑Free and Concentrated Ascites 
Reinfusion Therapy
Paracentesis is often considered to be the mainstay treat-
ment for MA. However, its effects can be short-lived with 
patients requiring repeat paracentesis, sometimes every few 
days [79]. Concerns around infection, particularly bacte-
rial peritonitis, restrict such acute parcentesis to being done 
in hospital. In patients requiring frequent ascitic drainage, 
semi-permanent tunneled catheter drainage systems, e.g. 
PleurX®, may be of benefit. The catheter is inserted into the 
peritoneal cavity via a subcutaneous tunnel, to help protect 
against infection, and then connected to a vacuum bottle via 
a drainage line. Patients are able to self-perform fluid drain-
age at home without the need to visit hospital, which con-
sequently leads to better management of symptoms, such as 
shortness of breath and abdominal pain [80]. As ascitic fluid 
is rich in proteins such as albumin and globulin repeat para-
centesis leads to a loss of body protein which can result in 
symptoms such as fatigue. Cell-free and concentrated ascites 
reinfusion therapy (CART) takes the fluid from paracentesis, 
filters out any cellular debris and concentrates the fluid pro-
tein before reinfusing it back into the patient [81]. Hanada 
et al. analysed CART on 51 patients with various malignan-
cies (16% diagnosed with pancreatic cancer) and found that 
the median time to repeat paracentesis was 27 days [82]. 
There was also a significant improvement in the intensities 
of all seven symptom modalities reported: fatigue, abdomi-
nal pain, abdominal distention, lack of appetite, nausea and 
vomiting, shortness of breath and insomnia.
Monoclonal Antibody Treatments
VEGF binding monoclonal antibody therapies such as bev-
acizumab and aflibercept have been shown to reduce the 
formation of malignant ascites in ovarian and colorectal can-
cer studies. In a phase II study, Colombo et al. investigated 
the use of aflibercept on MA in 16 patients with epithelial 
ovarian cancer [83]. They showed that the repeat paracen-
tesis response rate was 62.5% and that the median time to 
repeat paracentesis was 4.5-fold greater with aflibercept at 
76.0 days than baseline at 16.8 days. As VEGF is a cause of 
ascitic fluid production in PB cancer, such approaches may 
also have relevance.
Journal of Gastrointestinal Cancer 
1 3
Catumaxomab is a monoclonal antibody which targets 
epithelial tumour cells expressing epithelial cell-adhesion 
molecule (EpCAM), as well as T cells via CD3. It also 
activates the Fcγ-receptor by its Fc domain [84]. In a 
phase II/III trial, patients with ovarian and non-ovarian 
cancer (9% pancreatic cancer) were randomised to catu-
maxomab with paracentesis or paracentesis alone. Both 
median puncture-free survival and median time to repeat 
paracentesis were significantly longer in the catumaxomab 
group at 46 days and 77 days, versus 11 days and 13 days 




Pancreatic adenocarcinoma has a strong association with 
hyperglycaemia with up to 80% of patients with pancre-
atic cancer recognised as having impaired glucose toler-
ance or clinical diabetes mellitus (DM) [85]. Although 
it is possible that DM may act as a risk factor for devel-
opment of pancreatic cancer, the exact relationship at a 
pathophysiological level is unclear. Pancreatic atrophy 
and disrupted blood flow due to tumour bulk may reduce 
islet cell number and function with reduced insulin 
secretion.
Presentation and Management
In most patients with pancreatic cancer, the manifesta-
tion of DM will be poor glycaemic control. However, 
occasionally patients will present with diabetic 
emergencies—particularly diabetic ketoacidosis (DKA). 
In reports of pancreatic adenocarcinoma presenting as 
DKA, patients have had a prior history of type 2 DM, 
which normally rarely causes DKA, and some associ-
ated precipitating factor such as pancreatitis or infec-
tion that may have been stimulated by the occult pan-
creatic cancer [86]. Further investigation of the patient 
revealed the pancreatic malignancy. Diabetic ketoacido-
sis is also associated with pancreatic glucagonoma and 
somatostatinoma. Although these tumours are very rare, 
they should be considered in the differential diagnosis. 
The slow growing nature of these tumours may result in 
repeat presentations with DKA without other particular 
symptoms [87].
The acute management of DKA across the world is 




Hypercalcaemia, defined as a serum adjusted  Ca2+above 
2.6 mmol/L, is a well-recognised cancer-associated prob-
lem, and although rarely observed in PB cancer, it may be 
more common in pancreatic neuroendocrine tumours [88].
Aetiology
Tumour production of parathyroid hormone-related polypep-
tide (PTH-rp) increases renal tubular calcium reabsorption 
and phosphate excretion, as well as acting on osteoblasts 
[89]. It can arise with extensive bone metastases, where 
release of tumour cytokines results in increased osteoclast 
activity and enhanced bone resorption.
Symptoms
Symptoms of hypercalcaemia depend on the plasma  Ca2+ 
level and include fatigue, muscle pain and weakness, anorexia 
and constipation. Severe hypercalcaemia can result in delir-
ium, stupor, coma, cardiac arrhythmia and renal failure [89].
Investigations
Serum biochemical assessment to confirm raised serum 
adjusted  Ca2+ (normal range 2.2–2.6 mmol/L), as well as 
renal function in case of dehydration and to guide bisphos-
phonate dosage. Mid-morning parathyroid hormone (PTH) 
level may be required to exclude endocrine related hyper-
calcaemia (usually low in malignancy-related hypercalcae-
mia). PTH-rp can also be measured and is highly specific for 
malignancy-related hypercalcaemia [90].
Management
This is guided by the level of serum calcium and symptoms. 
Eliminate iatrogenic causes of hypercalcaemia (Ca 2+ and Vit 
D3 supplements, thiazide diuretics). If evidence of dehy-
dration and renal impairment administration of IV fluids is 
advised. Bisphosphonates, e.g. zoledronic acid, should be 
administered concurrently with IV fluid as the hypocalcae-
mic effect starts within 2–4 days.
Calcitonin can be used given its prompt effect and favour-
able side effect profile; however, the response is short lived. 
Patients with refractory hypercalcaemia should be consid-
ered for denosumab, an inhibitor of the receptor activator 
of nuclear factor κB ligand (RANKL). Cinacalcet (a cal-
cimimetic agent which directly lowers PTH levels) should 
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be considered in patients with resistant hypercalcemia as a 
result of PTH over production [91].
Complications from Management
During the rehydration, it is important to monitor fluid bal-
ance and ensure that patient is not developing overload. 
Osteonecrosis of the jaw is a known side effect from bis-
phosphonates and RANK treatment. Dental history and 
examination are important before proceeding with treatment.
Syndrome of inappropriate antidiuretic hormone 
secretio (SIADH)
Frequency
The syndrome of inappropriate ADH (SIADH) production 
is the most common cause of euvolemic hyponatraemia and 
in cancer patients can be caused by ectopic ADH secretion. 
SIADH in pancreaticobiliary malignancies is very uncom-
mon with, to date, a total of 13 case reports of documented 
ectopic ADH production in pancreatic and pancreatic neu-
roendocrine tumours.
Clinical Presentation
SIADH presents with hyponatraemia and symptoms are 
related to severity and acuteness of onset. The concern is 
regarding fluid shifts resulting in cerebral oedema. This 
may be suggested in patients with new onset moderate, 
or worse, hyponatraemia  (Na+  < 130 mmol/L) presenting 
with symptoms ranging from headache, nausea and vom-
iting to bradycardia, hypertension, convulsions and coma. 
Conversely, patients with chronic hyponatraemia are often 
asymptomatic.
Investigations
Checking renal function, serum Na + (S.Na +), serum osmo-
lality and urinary Na + and osmolality will provide adequate 
information to diagnose SIADH. Cortisol and thyroid 
function test can help to exclude other possible causes of 
hyponatremia.
Management
Mainstay of treatment is to control the underlying malig-
nancy. Fluid restriction to 500 ml/day is helpful in mild 
cases, and effect may be transient in nature. For severe 
and symptomatic hyponatremia, hypertonic saline is rec-
ommended, aiming to increase S.Na + by 0.5–1 meq/l/h; 
symptoms improve with 4–5% correction of the S. Na + . 
Appropriate endocrinology advice is crucial in treating 
cancer-related hyponatremia and discuss about starting tolvap-
tan, an oral elective vasopressin V2-receptor antagonist that 
is approved for euvolemic and hypervolemic hyponatremia 
[92].
Complications from Management
Central pontine myelinolysis is a known side effect of fast 
correction of hyponatremia, manifested by sleepiness, hal-
lucination, confusion tremors, slurred speech and weakness.
Neurological Emergencies
Metastatic Spinal Cord Compression (MSCC)
Frequency
Metastatic spinal cord compression (MSCC)  is an onco-
logical emergency that needs  urgent management. More 
than 50% of MSCC diagnosis is associated with prostate, lung 
or breast cancer. In patients with GI cancer including hepa-
tobiliary MSCC at diagnosis or during the course of disease 
is rare (2%).
Symptoms
Pain is the most common presentation in > 90% of cases. 
This can be local or radicular in nature, often described as a 
new pain or change in character of previous pain. The motor, 
sensory and autonomic signs occur late in the evolution of 
MSCC and will be distributed below the level of the cord 
compression and associated with poor outcome.
Investigations
Investigation is directed to confirm the diagnosis of MSCC 
and give information about the extent of the compression. 
Whole spine MRI is the investigation of choice. If MRI is 
contraindicated, CT whole spine could provide useful infor-
mation. Assessment of underlying cancer status is important 
as development of MSCC could only be part of disseminated 
cancer progression [93].
Management
All patients with suspected MSCC should be admitted to 
hospital, placed on flat bed rest, log rolled, started on high-
dose dexamethasone with PPI cover [93]. Once MSCC is 
diagnosed on imaging, spinal stability should be assessed 
Journal of Gastrointestinal Cancer 
1 3
and documented [93]. Discussion about definitive man-
agement will depend on prognosis based on cancer stage, 
response to treatment and patient’s fitness. Treatment 
options include surgery, radiotherapy or best supportive 
care. A definitive treatment plan—either radiotherapy or 
surgery—should be established as soon as possible, ideally 
within 24 h of the diagnosis. In pancreatic cancer, most of 
the patients have poor prognosis due to stage IV disease and 
most likely they will be treated with radiotherapy [94].
Complications of Treatment
Complication of treatment could be related to spinal surgery 
including acute and long-term surgical squealae. Acute com-
plication such as bleeding during or shortly after surgery and 
iatrogenic inter-operative spinal cord injury are less common 
in specialised neurosurgical centres. Radiotherapy can cause 
local irritation to the skin and tissues surrounding spinal 
cord. Increased pain could be one of the early symptoms 
before gaining benefit from radiotherapy. Radiotherapy-
induced myelitis is less common as most of the patients are 
on steroid at the time of treatment [94].
Brain Metastases
Frequency
Brain metastases from gastrointestinal cancer is around 4%, 
and they are extremely rare (0.2%) in pancreatic cancer [95].
Symptoms
Headache in combination with nausea and vomiting are 
common symptoms as manifestation of increase intracranial 
pressure. Functional impairment and symptoms depend on 
the localisation of the metastases.
Investigations
Contrast-enhanced MRI is the preferred imaging study to 
provide information about site size and number of brain 
metastasis and also provide information about CSF flow 
and possible hydrocephalus. CT brain with contrast is also 
helpful but is less sensitive compared to MRI, and it should 
only be performed if MRI is not available or contraindi-
cated. Assessment of underlying cancer status is important 
as development of brain metastases could only part of dis-
seminated cancer progression [93].
MRI is helpful as it gives good information about menin-
ges as some patients develop leptomeningeal disease. The 
prognosis of these patients is very poor with a survival of 
only a few months [93].
Management
Corticosteroids are useful in the initial management of 
symptoms suggesting increased intracranial pressure. Defini-
tive treatment depends on the overall prognosis, extracranial 
disease control and patients’ fitness. Brain surgery and/or 
radiotherapy (whole brain or stereotactic) should be consid-
ered in patient with good prognosis and controlled extrac-
ranial disease. Patient with limited prognosis but remain 
functionally well (good PS) could be considered for systemic 
therapy [93].
Conclusion
It is evident that patients with pancreaticobilliary malig-
nancies are at increased risk of a wide variation of medical 
emergencies. Clinical knowledge, early recognition and col-
laboration with the relevant specialties are critical to manage 
these complications effectively. Understanding of patients’ 
prognosis and overall clinical condition would aid to tailor 
treatment options and manage expectations.
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